Comparing different methods of determining whether gliomas are missing arms 1p and 19q of the chromosomes
Over the last year, Cochrane Neuro-Oncology have been publishing a series of new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which was published in March 2022, looking at the evidence on some of the tests that might help in planning the treatment of patients with a glioma. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - March 7, 2022 Category: General Medicine Authors: Cochrane Source Type: podcasts
Long-term effects of radiotherapy for glioma treatment on brain functioning
In March 2021, the Cochrane Neuro-Oncology Group published a series of eight new complex systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by people in this area using James Lind Alliance Priority Setting Partnership methods, which bring together patients and the public with practitioners. In this podcast, one of the Group ’s consumer representatives, Helen Bulbeck, talks with author Robin Grant, a consultant neurologist involved in the Edinburgh Centre for Neuro-Oncology in the UK about the review of the long-term neurocognit...
Source: Podcasts from The Cochrane Library - March 19, 2021 Category: General Medicine Authors: Cochrane Source Type: podcasts
Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly M...
Author: Annual-Meeting
Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts
Radiological Phenotyping For Glioma Study Outcomes
Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at AIG Discusses Radiological Phenotyping For Glioma Study Outcomes. At ESMO Oncology Conference - Muni...
Author: kidneycancer
Added: 10/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 26, 2018 Category: Cancer & Oncology Source Type: podcasts
IDH-specific vaccine for high-grade gliomas
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer ...
Author: VJOncology
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Gliomas in Mid-Line Locations have Distinct Make Up Defined by epigenetic and behavior
Andrew Chi, MD, NYU Medical Oncology Associates Explains how Gliomas in Mid-Line Locations are Distinct in Both Genetic Makeup and Behavior.
Author: Cancer-News
Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts
NYU is 1st Actively Enrolling Site for ONC201 in Adults With Recurrent H3 K27M High-grade Glioma Trial
Andrew Chi, MD, PhD at NYU Explains How NYU is 1st Actively Enrolling Site for ONC201 in Adults With Recurrent H3 K27M High-grade Glioma Trial.
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Patients Enroll with Any Histologic Glioma Need to have regressive tumor after 1st line of therapy
Andrew Chi, MD, NYU Medical Oncology Associates Explains how Patients Enroll with Any Histologic Glioma Need to have regressive tumor after 1st line of therapy in a Press Release.<br />
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Phase 2 Clinical Trial of ONC201 in Patients with Glioma that has H3 K27M Mutation
Andrew Chi, MD, PhD at NYU Explains Phase 2 Clinical Trial of ONC201 in Patients with Glioma that has H3 K27M Mutation.
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Phase 2 Clinical Trial of ONC201 Mutation K27M defines distinct Glioma
Andrew Chi, MD, NYU Medical Oncology Associates Explains Phase 2 Clinical Trial of ONC201 Mutation K27M defines distinct Glioma in a Press Release.<br />
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
K27M Mutations are Rare within Gliomas, an Already Rare Cancer Type
Andrew Chi, MD, PhD at NYU explains how K27M Mutations are Rare within Gliomas, an Already Rare Cancer Type.
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Gliomas are Rare Cancers K27M comprised a couple percentage of all Gliomas
Andrew Chi, MD, NYU Medical Oncology Associates explains how Gliomas are Rare Cancers K27M comprised a couple percentage of all Gliomas in a Press Release.<br />
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Gliomas in Mid-Line Locations have Distinct Make Up Defined by epigenetic and behavior
Andrew Chi, MD, NYU Medical Oncology Associates Explains Gliomas in Mid-Line Locations have Distinct Make Up Defined by epigenetic and behavior in a Press Release.<br />
Author: Cancer-News
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy in Glioma Study in the neoadjuvant setting
Santosh Kesari, MD, Immunotherapy in Glioma Study in the neoadjuvant setting at the 2018 Oncology Summit in Huntington Beach, CA <br /><br />Go to: <a target='_blank' href='http://www.moasc.org'>http://www.moasc.org...</a> for more information
Author: moasc
Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts
